Biotransformation of 3-(3′,5′ -Dichlorophenyl)-5,5-dimethyl oxazolidine-2,4-dione

Abstract

Using 3-(3′,5′-dichlorophenyl)-5,5-dimethyloxazolidine-2,4-dione labeled with ¹⁴C or ³H, absorption, excretion, and tissue distribution in male Wistar rats were studied, and metabolites excreted were identified. At the dosage rates of 100, 300, 1000 and 3000 mg/kg, the maximum excretion of orally administered radioactivity occurred within 24 hr. Increase in the dosage rate was paralleled by decrease in the proportion of urinary elimination. Essentially all the radioactivity was excreted in 2 weeks. DDOD level was generally low in most tissues. Adipose tissue contained higher radioactivity compared with others. Most of the urinary metabolites identified were characterized by hydroxylation at the 4′ position of the benzene ring moiety, and hydrolytic or oxidative modification of the oxazolidine ring portion.